Literature DB >> 25557642

Hemangioma Activity and Severity Index (HASI), an instrument for evaluating infantile hemangioma: development and preliminary validation.

Kristina Semkova1, Jana Kazandjieva, Miroslava Kadurina, Nikolay Tsankov.   

Abstract

BACKGROUND: Infantile hemangiomas (IHs) are the most common benign vascular tumors of infancy. Their evaluation is important and requires the use of a unified scoring system.
OBJECTIVES: We designed a novel scoring index, the Hemangioma Activity and Severity Index (HASI), for the clinical evaluation of IHs. The purpose of this pilot study was to validate the HASI.
METHODS: The HASI was evaluated for validity by an external panel of experts. The reliability study included 59 children with superficial and mixed hemangiomas. Patients attended an assessment visit and a subsequent visit three days later for a second scoring. They were then followed up monthly for six months and scored at each visit by two investigators separately.
RESULTS: Interclass correlation coefficients (ICCs) for inter-rater reliability were 0.82 (95% confidence interval [CI] 0.75-0.88) for IH activity and 0.94 (95% CI 0.91-0.96) for IH severity. Intra-rater reliability was high, with negligible mean differences of 0.3 and 0.4 points between the two ratings. The average time required to complete the scoring was 2.5 minutes.
CONCLUSIONS: Our preliminary studies on the HASI show promising results in terms of its clinical utility and applicability in practice. It could be used by physicians as an objective instrument for the scoring of IHs.
© 2014 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2014        PMID: 25557642     DOI: 10.1111/ijd.12646

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  3 in total

1.  Infantile Hemangiomas with Minimal and Arrested Growth: Clinical Features and Treatment Outcomes with 0.5% Topical Timolol Maleate.

Authors:  Kyung-Nam Bae; Kihyuk Shin; Hoon-Soo Kim; Byung-Soo Kim; Moon-Bum Kim; Hyun-Chang Ko
Journal:  Ann Dermatol       Date:  2021-09-08       Impact factor: 1.444

2.  Commentary: Propranolol for infantile hemangiomas - The intralesional route.

Authors:  Devjyoti Tripathy
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

3.  Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment.

Authors:  Kanokporn Chitpiromsak; Leelawadee Techasatian; Charoon Jetsrisuparb
Journal:  BMJ Paediatr Open       Date:  2021-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.